NCT05170542招募中2 期
A Single-arm, Phase II Study of Camrelizumab Combined With S-1 Maintenance After First-Line Induction Chemotherapy in Patients With HER2 Negative Advanced Gastric Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 42
- 试验地点
- 1
- 主要终点
- Progression-Free Survival (PFS)
研究概览
简要总结
In this study, We investigated the efficacy and safty of camrelizumab combined with S-1 maintenance after first-line induction chemotherapy for GC. Patients without progressive disease after 4-6 weeks of first-line chemotherapy with SOX will be treated with camrelizumab combined with S-1.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subjects aged from 18 to 75 years old;
- •Subjects with histologically confirmed unresectable locally advanced or metastatic adenocarcinoma of the stomach or gastro-esophageal junction (GEJ);
- •Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at trial entry;
- •Disease must be measurable by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1);
- •Estimated life expectancy of more than 3 months;
- •Adequate haematological, hepatic and renal functions defined by the protocol;
- •Negative blood pregnancy test at Screening for women of childbearing potential; Highly effective contraception for both male and female subjects if the risk of conception exists;
排除标准
- •Concurrent anticancer treatment such as chemotherapy, radiotherapy, targeted or immunotherapy;
- •Tumor shown to be human epidermal growth factor 2 plus (HER2+);
- •Previous malignant disease (other than gastric cancer) within the last 5 years with the exception of basal or squamous cell carcinoma of the skin or carcinoma in situ (bladder, cervical, colorectal, breast);
- •Severe infection (e.g. need for intravenous antibiotics, antifungal or antiviral drugs) occurred within 4 weeks before the first administration, or fever (>38.5%) of unknown reason occurred during the screening period/before the first administration；
- •Any active autoimmune disease or history of autoimmune disease (such as interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (can be included after hormone replacement therapy)); The subjects with childhood asthma who had been completely relieved and did not need any intervention or vitiligo in adulthood could be included, but the subjects who needed bronchodilator for medical intervention could not be included;
- •Patients with congenital or acquired immune deficiency, such as human immunodeficiency virus (HIV) infection, active hepatitis B (HBV DNA ≥ 500 IU / ml), hepatitis C (HCV antibody positive and HCV-RNA higher than the detection limit of the analytical method), or co infection of hepatitis B and hepatitis C;
- •Used immunosuppressive drugs within 14 days before the first dose of study drug, excluding nasal and inhaled corticosteroids or physiological doses of systemic corticosteroids;
- •Accination with live or live/attenuated viruses within 28 days of the first dose of camrelizumab and while on trial is prohibited except for administration of inactivated vaccines;
- •History of uncontrolled intercurrent illness including hypertension, active infection, diabetes or cardiac diseases or symptoms;
- •Prior organ transplantation, including allogeneic stem-cell transplantation； Other protocol-defined inclusion/exclusion criteria could apply.
研究组 & 干预措施
Camrelizumab+S-1
Experimental
干预措施: Camrelizumab+S-1 (Drug)
结局指标
主要结局
Progression-Free Survival (PFS)
时间窗: From the start of randomization to a minimum of 42 months
PFS is defined as time (in months) from date of randomization to the date of the first documentation of objective progressive disease (PD) or death due to any cause in the absence of documented PD (whichever occurs first). PFS will be determined according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) based on investigator response assessment.
次要结局
- Objective Response Rate（ORR）(From the start of randomization to a minimum of 42 months)
- Overall Survival（OS）(From the start of randomization to a minimum of 42 months)
- Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0(From the the first dose of study drug administration up to 28 days after the last dose of study drug administration, assessed up to 3.5 years)
- Disease Control Rate (DCR)(Time Frame: From the start of randomization to a minimum of 42 months)
研究者
WangXiang
chief physician
Peking Union Medical College Hospital
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)Triple Negative Breast CancerNCT05447702West China Hospital35
进行中（未招募）
2 期
Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC PatientsSquamous Cell Carcinoma of Head and NeckNCT05673577Fudan University40
Unknown
2 期
Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung CancerSmall Cell Lung CarcinomaNCT04901754Henan Cancer Hospital38
尚未招募
2 期
A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck CancerHead and Neck NeoplasmsNCT04405154West China Hospital32
招募中
2 期
PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical CancerCervical CarcinomaChemoradiotherapyAnti-programmed Cell Death Receptor 1ImmunotherapyImmune Checkpoint InhibitorSurvival OutcomesAdverse EventsEarly Stage Cervical CancerLocally Advanced Cervical CancerNCT05311566Lei Li92